Aviva PLC Exelixis, Inc. Transaction History
Aviva PLC
- $36.8 Billion
- Q4 2024
A detailed history of Aviva PLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Aviva PLC holds 17,228 shares of EXEL stock, worth $639,675. This represents 0.0% of its overall portfolio holdings.
Number of Shares
17,228
Previous 24,927
30.89%
Holding current value
$639,675
Previous $646,000
11.3%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding EXEL
# of Institutions
564Shares Held
251MCall Options Held
1.45MPut Options Held
1.13M-
Black Rock Inc. New York, NY33.5MShares$1.24 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA29.4MShares$1.09 Billion0.02% of portfolio
-
Farallon Capital Management LLC San Francisco, CA23.4MShares$870 Million4.16% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny15.3MShares$568 Million0.8% of portfolio
-
State Street Corp Boston, MA11.4MShares$424 Million0.02% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $11.9B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...